[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"femoropopliteal-artery-occlusion\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:femoropopliteal-artery-occlusion":74},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100624182",false,"NCT07406308","A Comparative Analysis of Mid- to Long-Term Outcomes: Paclitaxel-Coated Balloon With Debulking Versus Paclitaxel-Coated Balloon Alone in the Treatment of Chronic Femoropopliteal Artery Occlusions","A Comparative Analysis of Mid- to Long-Term Outcomes of Paclitaxel-Coated Balloon Angioplasty With Adjunctive Debulking Versus Paclitaxel-Coated Balloon Angioplasty Alone for the Treatment of Chronic Femoropopliteal Artery Occlusions","DCB-Debulk-COM","Inclusion Criteria:\n\n* Subject age 18-85yrs.\n* Subject has been informed of the nature of the study, agrees to participate, and has signed a Medical Ethics Committee approved consent form.\n* Subject understands the duration of the study, agrees to attend follow-up visits, and agrees to complete the required testing.\n* Rutherford category 2-5.\n* Subject has atherosclerotic de novo, non-stented restenotic, or in-stent restenotic\u002Focclusive lesions in the superficial femoral artery (SFA) and\u002For popliteal artery (P1 segment).\n* Patent inflow artery with stenosis \\\u003C30% by visual estimation (or by core lab assessment if available) and at least 1 infrapopliteal artery to the ankle (\\\u003C50% diameter stenosis).\n* A guidewire has successfully traversed the target treatment segment.\n\nExclusion Criteria:\n\n* Subject presents with acute arterial embolism or thrombosis requiring thrombectomy or thrombolysis for limb ischemia.\n* Subject has arterial occlusion caused by thromboangiitis obliterans (Buerger's disease) or other forms of immune-mediated vasculitis.\n* Subject has undergone surgery on the target vessel within the past 3 months, or has experienced repeated failures of endovascular therapy and is deemed unsuitable for further endovascular intervention.\n* Subject has an uncontrolled thrombophilia or hypercoagulable state.\n* Subject has a severe systemic disease (e.g., malignancy) with a life expectancy of less than 1 year.\n* Subject has contraindications or intolerance to antiplatelet\u002Fanticoagulant medications, such as aspirin, clopidogrel, or heparin.\n* Subject is pregnant or breastfeeding.\n* Subject meets one or more of the following conditions: chronic renal insufficiency (SCr ≥ 2.5 mg\u002FdL) or on regular dialysis; cardiovascular or cerebrovascular surgery within the past 1 month; or severe sequelae from a major stroke.\n* Subject has a known allergy to nitinol alloy, paclitaxel, or contrast agents.","ALL","18 Years","85 Years",{"count":20,"type":21},408,"ESTIMATED","INTERVENTIONAL",[24],"EARLY_PHASE1","This study aims to compare mid-to long-term outcomes of paclitaxel-coated balloon angioplasty with adjunctive debulking versus paclitaxel-coated balloon angioplasty alone for the treatment of chronic femoropopliteal artery diseases.",[27],"Femoropopliteal Artery Occlusion",[27,29,30],"Drug-Coated Balloon","debulking procedures","NOT_YET_RECRUITING","2026-02-05",{"date":34,"type":35},"2026-02-12","ACTUAL",{"date":37,"type":21},"2026-04-20",{"date":39,"type":21},"2028-05-30",{"name":41,"class":42},"Peking Union Medical College Hospital","OTHER",1,{"id":45,"slug":4,"hasResults":10,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":60,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":43},"100522426","NCT06082466","FRAMED Infrainguinal Venous Bypass Versus Conventional Autologous Bypass Trial","Framed IVB","Inclusion Criteria\n\n* Age at least 18 years\n* Informed consent form with signature\n* Rutherford Category 3 (\\\u003C200m) or chronic critical ischemia (Rutherford Category 4-6)\n* Assured inflow and recipient artery.\n\nExclusion Criteria\n\n* Pregnant or breastfeeding women\n* Active infection or sepsis\n* Acute ischemia\n* Endovascular procedure in the region to be treated.\n* Vein with outer diameter \\\u003C3.5 mm or \\>8 mm under pressure.\n* Spliced Veins.\n* Known allergy to the cobalt-chromium alloy (ASTM 1058) or its components (Cobalt-Chromium-Iron-Nickel-Molybdenum).\n* Vasculitis\n* Coagulopathy\n* Radiation therapy near the anastomosis",{"count":51,"type":21},110,[53],"NA","The purpose of this clinical trial is to analyze patency after autologous infrainguinal bypass surgery in patients receiving a venous conduit versus a covered venous conduit.",[56,27,57,58,59],"Peripheral Arterial Occlusive Disease","Femoropopliteal Stenosis","Critical Limb-Threatening Ischemia","Claudication, Intermittent",[61,62,63],"Extraluminal Bypass Stenting","Autologous Vein Graft","Bypass Extremity Graft","RECRUITING","2023-11-20",{"date":67,"type":35},"2023-11-21",{"date":69,"type":35},"2023-09-11",{"date":71,"type":21},"2027-09",{"name":73,"class":42},"Paracelsus Medical University",""]